Pharmacokinetics of low molecular weight dermatan sulphate (Desmin) in different cohorts of patients

Thrombosis Research

Volumn 90, Issue 3, 1998, Pages 139-145

  Saivin, Sylvie ^a   Carrie, Didier ^b   Escourrou, Jean ^a   Duchene, Patrick ^c   Zamboni, Villiam ^d   Barbanti, Miriam ^d   Palazzini, Ernesto ^d   Houin, Georges ^a  

^a CHU RANGUEIL   (France)

^b CHU PURPAN   (France)

^c ADME Bioanalyses   (France)

^d Alfa Wassermann SpA   (Italy)

Author keywords

Acenocoumarol; Desmin; Hepatic insufficiency; LMW dermatan sulphate; Peptic ulcer; Pharmacokinetics

Indexed keywords

ACENOCOUMAROL; BILIRUBIN; BLOOD CLOTTING FACTOR 10A INHIBITOR; CHROMOGENIC SUBSTRATE; DESMIN; HEPARIN; HEPARIN COFACTOR II;

ADULT; ANTICOAGULANT THERAPY; AREA UNDER THE CURVE; ARTERY THROMBOSIS; ARTICLE; CHOLESTASIS; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIGESTIVE SYSTEM ULCER; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LIVER FAILURE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBIN TIME; VEIN THROMBOSIS;

EID: 0032079573     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(98)00040-1     Document Type: Article

References (30)

1. Ofosu F.A., Fernandez F., Anvari N., Caranobe C., Dol F., Cadroy Y., Petitou M., Mardiguian J., Sié P., Boneu B. Further studies on the mechanism for the antithrombotic effects of polysaccharides in rabbits. Thromb Haemost. 60:1988;188-192.
2. Sié P., Ofosu F.A., Fernandez F., Buchanan M.R., Petitou M., Boneu B. Respective role of antithrombin III and heparin cofactor II in the in vitro coagulant effect of various polysaccharides. Br J Haematol. 64:1986;707-714.
3. Tollefsen D.M., Petska C.A., Monafo W.J. Activation of heparin cofactor II by dermatan sulfate. J Biol Chem. 258:1983;6713-6716.
4. Desnoyers P., Bara L., Samama M. Dermatan sulphate et prévention des thromboses veineuses expérimentales. Path Biol. 37:1989;759-767.
5. Fernandez F., Ryn J.V., Ofosu F.A. The haemorrhagic and antithrombotic effects of dermatan sulphate. Br J Haematol. 64:1986;309-327.
6. Van Ryn M.J., Gray E., Weber E., Ofosu F.A., Buchanan M.R. Effects of sulphated polysaccharides on inhibition of thrombus formation initiated by different stimuli. Thromb Haemost. 61:1989;7-9.
7. Abbadini M., Zhu G.J., Maggi A., Pangrazzi J., Donati M.B., Mussoni L. Dermatan sulphate induces plasminogen activator release in the perfused rat hindquarters. Blood. 70:1987;1858-1860.
8. Maggi A., Abbadini M., Pagella P.G., Borowska A., Pangrazzi J., Donati M.B. Antithrombotic properties of dermatan sulphate in a rat venous thrombosis model. Haemost. 17:1987;329-335.
9. Legnani C., Palareti G., Biagi R., Ludovici S., Maggiore L., Milani M.R., Cocherri S. Acute and chronic clotting and fibrinolytic effect of a new low molecular weight dermatan sulphate (desmin 370) in healthy subjects. Eur J Clin Pharmacol. 47:1994;247-252.
10. Colucci M., Trigiani R., Cavallo L.G., Chiumarulo P., Barbanti M. Therapeutic effect of a low molecular weight dermatan sulfate in experimental venous thrombosis, comparison with hirudin and Heparin. Fibrinolysis. 6:1992;136.
11. Barbanti M, Calanni F, Milani MR, Marchi E, Semeraro N, Colucci M. Therapeutic effect of a low molecular weight dermatan sulfate (Desmin 370) in rat venous thrombosis - Evidence for an anticoagulant independent mechanism. Thromb Haemost 193;69:147-51.
12. Barbanti M., Calanni F., Marchi E., Semeraro N., Colucci M. Desmin 370, a low molecular weight dermatan sulphate reduces the weight of preformed thrombi in rats made afibrinogenemic by ancrod. Thromb Haemost. 73:1995;287-290.
13. Bergonzini G.L., Bianchini P., Hoppensteadt D., Parma B., Osima B., Walenga J.M., Fareed J. Pharmacokinetics of native and low molecular weight dermatan sulfate. Preliminary results in rats and primates Sem Thromb Haemost. 17:1991;235-239.
14. Dettori A.G., Galli G., Manotti C., Palazzini E. Pharmacological activity of a low molecular weight dermtan sulphate (Desmin) in healthy volunteers. Thrombos Haemostasis. 20:1994;259-265.
15. Dol F., Petitou M., Lormeau J.C., Choay J., Caranobe C., Sié P., Saivin S., Houin G., Boneu B. Pharmacological properties of a low molecular weight dermatan sulfate. Comparison with unfractionated dermatan sulfate J Lab Clin Med. 15:1990;43-51.
16. Saivin S., Dol F., Caranobe C., Petitou M., Lormeau J.C., Sié P., Houin G., Boneu B. Influence of the molecular weight upon the anticoagulant and pharmacokinetic properties of dermatan sulfate in the rabbit. Thromb Res. 66:1992;527-535.
17. Cucinotta D., Manopulo R., Galati M., Zamboni V., Palazzini E., Barbanti M., Milani M.R. Pharmacodynamics of a new low molecular weight dermatan sulfate after a single subcutaneous injection in elderly patients with chronic venous disorders. A phase I trial Cur Ther Res. 55:1994;1492-1500.
18. Traini A.M., Cervi V., Melandri G., Palazzini E., Zamboni V., Semprini F., Candiotti N., Branzi A. Pharmacodynamics characteristic of low-molecular weight dermatan sulphate after a single subcutaneous administration in acute myocardial infarction. J Int Med Res. 22:1994;323-331.
19. Dawes J. The pharmacokinetics of LMW Dermatan sulphate. Long term persistence of intact material Thromb Haemost. 69:1993;339-343.
20. Tamagnone G., Barbanti M. Desmin-370. Drug of the Future. 19:1994;638-640.
21. Bara L., Mardiguian J., Samama M. In vitro effect on Heptest® of low molecular weight Heparin fractions and preparations with various anti-IIa and anti-Xa activities. Thromb Res. 57:1990;585-592.
22. Dupouy D., Sié P., Dol F., Boneu B. A simple method to measure dermatan sulfate at submicrogram concentration in plasma. Thromb Haemost. 60:1988;236-239.
23. Gomeni R. Pharm. An interactive graphic program for individual and population pharmacokinetic parameters estimation Comp Biomed Res. 14:1984;25-34.
24. Schuirmann D.J. A comparison of the two one-sided tests procedure and the power approach for assesssing the equivalence of average bioavailability. J Pharmacokin Biopharm. 15:1987;657-680.
25. Steinijans V.W., Hartmann M., Huber R., Radtke H.W. Lack of interaction as an equivalence problem. Int J Clin Pharmacol Ther Toxicol. 29:1991;323-328.
26. Dettori A.G., Milani M.R., Manotti C., Zamboni V., Palazzini E., Barbanti M. Pharmacology of Desmin (low molecular weight dermatan sulphate) in healthy volunteers following intravenous bolus administration of different dosages (200, 400, 800 mg). Thromb Res. 79:1995;249-260.
27. Brieger D., Dawes J. Low molecular weight Heparin is responsible for the anti-Xa activity of Desmin 370. Thromb Haemost. 75:1996;286-291.
28. Caranobe C., Barret A., Gabaig A.M., Dupouy D., Sié P., Boneu B. Disappearance of circulating Anti Xa activity after intravenous injection of standard Heparin and of low molecular weight Heparin (CY 216) in normal and nephrectomized rabbits. Thromb Res. 40:1985;129-133.
29. Brozovic M. Acquired disorders of coagulation. Bloom A.L., Thomas D.P. Haemostasis and Thrombosis. 1987;519-534 Edinborough, Churchill Livingstone.
30. Furie B. Coagulation disorders associated with liver disease. Hoffman R., Benz E.J., Shattil S.J., Cohen H.J. Hematology. Basic Principle and Practice. 1991;1377-1380 Edinborough, Churchill Livingstone.